Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Jonathan Watanabe, PharmD, MS, PhD

Photo of Jonathan Watanabe, PharmD, MS, PhD
Title(s)Professor, Clinical Pharmacy
SchoolSchool of Pharmacy
Address490 Illinois Street, #32Q
San Francisco CA 94158
ORCID ORCID Icon0000-0002-2543-5305 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Washington, School of Pharmacy, Comparative Health, Outcomes, Policy, and Economics (CHOICE) Institute, Seattle, WAPhDPharmaceutical Outcomes, Research, and Policy
    University of Washington/Allergan Global Health Economics and Outcomes Research Fellowship, Seattle, WA and Irvine, CA. Health Economics and Outcomes Research
    University of Washington, School of Pharmacy, Comparative Health, Outcomes, Policy, and Economics (CHOICE) Institute, Seattle, WAMSPharmaceutical Outcomes, Research, and Policy
    University of Southern California, School of Pharmacy, Los Angeles, CAPharmDPharmacy
    University of Washington, Seattle, WABSZoology
    Board of Pharmacy SpecialtiesBoard Certification in Geriatric Pharmacy (BCGP)
    Collapse awards and honors
    American Society of Consultant Pharmacists. Leading global organization for geriatric pharmacy2025  - 2025George F. Archambault Award
    UC Irvine, Institute for Precision Health2024  - 2024UC Irvine Institute for Precision Health Distinguished Lecture. Inaugural Distinguished Lecture Speaker
    California Institute for Regenerative Medicine Meeting (CIRM) 2023  - 20236th Annual California Institute for Regenerative Medicine Meeting (CIRM) Alpha Clinic Network, Keynote Speaker
    National Academy of Medicine Council2018  - 2021National Academy of Medicine Emerging Leaders in Health and Medicine Program Scholar
    Peter Lamy Center on Drug Therapy and Aging at the University of Maryland.2021  - 2021Peter P. Lamy Memorial Lecture Award. Keynote Speaker and Award recipient at American Society of Consultant Pharmacists Annual Meeting.
    Chapman University School of Pharmacy2021  - 2021Keynote Speaker, Chapman University School of Pharmacy Research Day
    PhRMA Foundation2020  - 2020PhRMA Foundation inaugural Value Assessment Challenge Award Paper
    UC San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences2020  - 2020White-Coat Keynote Speaker, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences Class of 2024
    University of Washington Pharmacy Alumni Association2019  - 2019Distinguished Alumni of the Year Award for Excellence in Pharmaceutical Sciences
    Get the Medications Right Institute. Tysons Corner, VA. 2019  - PresDistinguished Fellow, Get the Medications Right Institute.
    National Academies of Sciences, Engineering, and Medicine Health and Medicine Division2019  - 2019Forum on Drug Discovery, Development, and Translation of the National Academies of Sciences, Engineering, and Medicine. Appointed Member. Reappointed 2023-2026.
    University of Washington Pharmacy Alumni Association2019  - 2019"Alumni Legend" Selection. One of initial five graduates selected for the University of Washington School of Pharmacy 125th Anniversary Celebration Awards Program.
    UC San Diego Cross-Cultural Center. 2017  - 2017Faculty-in-Residence. UC San Diego Cross-Cultural Center.
    Academy of Managed Care Pharmacy (AMCP)2017  - 2017Gold Medal Research Poster Award. Academy of Managed Care Pharmacy (AMCP) Annual Meeting.
    National Academies of Medicine. Sponsored by American Association of Colleges of Pharmacy and American College of Clinical Pharmacy2016  - 2018National Academy of Medicine (formerly the Institute of Medicine) Anniversary Fellow in Pharmacy.
    NIH, National Institute on Aging2016  - 2018National Institutes of Health (NIH) Loan Repayment Program Recipient.
    Academy of Managed Care Pharmacy2014  - 2014Platinum Award for Top Research Abstract. Academy of Managed Care Pharmacy (AMCP) Nexus Conference. Boston, MA.
    American Association of Neuromuscular and Electrodiagnostic Medicine2010  - 2010President's Research Initiative Award, American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting.
    University of Southern California School of Pharmacy2007  - 2007Harold Miller Leadership Award
    Phi Lambda Sigma, National Pharmacy Leadership Society.2007  - PresInductee, Phi Lambda Sigma, National Pharmacy Leadership Society.
    University of Southern California School of Pharmacy2006  - 2006Distinguished Service Award

    Collapse Research 
    Collapse research activities and funding
    Drug-Related Complications
    APhA/JCPP CA-0281539Jan 1, 2026 - Jun 30, 2027
    Role: PI
    Description: The project goal is to examine medical events attributable to US medications by an established UCSF pharmacist-scientist investigator and his UCSF-based research unit.
    California: Integrating Pharmacists into Health Care Teams
    CDPH (CDC Parent Grant) 24-10427Aug 15, 2025 - Jun 28, 2028
    Role: Co-I
    Description: Pursuant to California Health and Safety Code Sections 131058 and 131085, Co-I will support Integrating Pharmacists into Health Care Teams by providing pharmacy network assessments and training and technical assistance (TTA) to Chronic Disease Control Branch (CDCB) A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes (T2DP) partners participating in these programs and to expand this to other pharmacy networks in California. Support federal investments for evaluating, assessing, and implementing evidence-based strategies to manage diabetes and improve health outcomes. In alignment with CDPH-CDCB, the deliverables under this agreement will focus on reducing health disparities and achieving health equity for priority populations.
    Effects of Socioeconomic and Racial/Ethnic Status on Biologic Disease-Modifying Antirheumatic Agents for Medicare Beneficiaries
    Arthritis Foundation Rheumatoid Arthritis Research Program Jan 1, 2025 - Dec 31, 2026
    Role: Co-I
    Description: The foundations of this proposal center on examining racial/ethnic and financial social determinants of health and how they may affect patient decision-making in the treatment experience for those with moderate-to-severe rheumatoid arthritis and Medicare insurance coverage. Provided guidance on study design, endpoint specification, and economic effects for anlayses utilizing Medicare claims data to demonstrate that race and ethnicity indirectly predispose those of lower socioeconomic status to forego self-administered biologic therapy due to higher patient cost-sharing, instead gravitating toward cheaper, office-administered biologic therapy instead.
    Global Definitions and Classifications of Biosimilar Therapeutics
    GSK 212679Nov 1, 2023 - Oct 31, 2025
    Role: PI
    Description: To identify and systematically compare the definitions given in different countries per region for biosimilar products that may apply to international standard definitions by agencies such as the United States Food and Drug Administration (FDA), World Health Organization (WHO), and European Medicines Agency (EMA). Lead research team for comprehensive literature, regulatory guidance, and scoping review applying PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) and global review of specified guidances from agencies of biosimilars and follow-on biologics.
    Medication Use Patterns and Patient Characteristics of Anti-SARS-CoV-2 Monoclonal Antibodies
    Syntropy Technologies PR58802Apr 1, 2022 - Mar 30, 2024
    Role: PI
    Description: Real-world data analysis of COVID-19 MAbs, vaccine effectiveness and impact, and medication outcomes for therapeutics, interventions, and modalities (egs. telemedicine, digital health tech) used for COVID-19 treatments and for evaluating care delivery during the Pandemic. Led research projects on therapeutics, interventions, health services, and outcomes on COVID-19-related analyses.
    Real World Evidence to Accelerate COVID-19 Therapeutics
    US Department of Health and Human Services (MITRE Corporation) 139961Nov 21, 2021 - Feb 9, 2022
    Role: Co-I
    Description: Project goals: Develop cohort and registry data that will be leveraged to produce real-world evidence (RWE) on the safety and effectiveness of mAbs which will, in turn, be used to develop and refine COVID-19 predictive models. Contribution and curation of real world data (RWD) to a centralized, secure data registry for evidence generation, and to help identify key challenges, mitigations, and promising practices for future patient care. Project includes data contribution, clinical input, and development of research questions to be answered by the registry through centralized analytics, including the following. Assisting in the identification of relevant data elements that will be of value to hospitals, health systems, clinicians, and others in the use of mAbs for qualifying patients, and providing these data elements for import into the centralized data registry. Providing research expertise and input in the development of key research questions that are critical for study design, analytics and evidence generation, and the review/interpretation of results. Providing technical guidance and assistance for the initiative in the sharing of data elements from electronic health record (EHR) systems . Tasks include the Participation in Creation of Study Governance Framework, Curation and Submission of mAb Relevant Patient Data to Centralized Registry, National Collaboration for Qualitative and Case Study Analyses for Effective mAb Usensated under this task order). Subsequent tasks include genomic sequencing of virus for mAbs recipients. Guide comparative effectiveness research approaches, specifically propensity score matching method, to evaluate the array of monoclonal antibody effectiveness for treatment during the Pandemic in collaboration with UCI project team and research team at MITRE.
    Prevalence, Trend, and Hospitalization Risk for Users of Potentially Inappropriate Medications in Older Adults”
    NIH/NIA Loan Repayment Program Sep 1, 2016 - Aug 30, 2018
    Role: PI
    Description: Applying a large, nationally representative database to ascertain the prevalence of use in seniors of potentially inappropriate medications that includes incidence of hospitalizations caused by adverse drug events and risk reduction in those that reduce use potentially inappropriate medications.
    The San Diego Geriatrics Workforce Enhancement Program (SD GWEP)
    HRSA U1WQHP28726Jul 1, 2015 - Jun 30, 2019
    Role: Co-I, Fellowship Director
    Description: The San Diego GWEP Collaborative (SDGWEPGEC) responds to the national, regional, and local workforce needs outlined in the Institute of Medicine’s (2008) report, "Retooling for an Aging America: Building the Healthcare Workforce" by developing a interprofessional development training program called Geriatric Scholars that will increase the number of physician, nurse, pharmacist, dentist, and other allied health providers in geriatrics through an interdisciplinary geriatrics clinical training experience. Program included annual interprofessional geriatrics symposium, 120 hour per years geriatric scholars certificate progam, Falls symposium, Care for Unhoused Older adults Seminar, Clinical PharmD Geriatrics Fellowship program, PharmD student internship at the San Diego Program for All-inclusive Care for the Elderly (PACE) Clinic. Served as Co-Investigator, Director of Quality Metrics Evaluation, Faculty, Pharmacy Intern Supervisor, and Geriatrics Fellowship Director for the San Diego GWEP Collaborative
    Estimating the value of anti-drug antibody screening for tumor necrosis factor-alpha inhibitors in patients with rheumatoid arthritis
    ALSAM Foundation ALSAM435Jul 1, 2015 - Jun 30, 2018
    Role: PI
    Description: A retrospective claims database analysis using the Truven MarketScan® commercial, medicare, and medicaid databases will be conducted to estimate the rate of 1st TNF-blocker treatment failure versus response (primary aim), and test for patient characteristics and costs associated with treatment failure versus response in RA patients who initiate a 1st TNF-blocker (secondary hypotheses). Associations of patient characteristics and cost with treatment failure versus response will be tested using regression models appropriate to the outcome. To estimate the incremental effectiveness and cost of ADAb screening as compared to no screening using a decision-analytic model (primary aim). Led the database cleaning, optimizing, and statistical analyses for all claims data analyses over the course of this 2 year project. I developed the statistical regression models applied and validated SAS codes for analyses. Supervised all research analysts involved in the analytics. Led Development of the decision analytic model and creation of final study report.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. ASHP and ASHP Foundation Pharmacy Forecast 2026: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems. Am J Health Syst Pharm. 2026 Jan 06; 83(2):71-101. DiPiro JT, Couldry R, Dopp AL, Kraus T, Vest TA, Chou J, Watanabe JH, Fretland K, Fabian TJ, Gosser R, Blind JE, Blackburn H, Gruenberg K, Merandi J, Cunningham FE, Hoffman JM. PMID: 41358375.
      View in: PubMed   Mentions:
    2. Innovations in Pharmacy Training and Sustainable Practice to Advance Patient Care: Proceedings of a Workshop. 2025. View Publication.
    3. Association of Baseline Comorbidities With First-Year Adherence to GLP-1 Receptor Agonists in Patients With Diabetes or Obesity: A Retrospective Cohort Study. Ann Pharmacother. 2025 Dec 07; 10600280251384637. Mai Z, Kornak J, Dufault SM, Strand MW, Reikes AR, Watanabe JH. PMID: 41355396.
      View in: PubMed   Mentions:
    4. Off-label policy through the lens of trazodone usage and spending in the United States. Health Aff Sch. 2025 Jul; 3(7):qxaf114. Kadiyala S, Chenoweth M, Watanabe JH. PMID: 40692815; PMCID: PMC12278056.
      View in: PubMed   Mentions:
    5. Trends in Pharmacological Treatment of Patients With New Onset Type 2 Diabetes: Usage Patterns in an Evolving Guideline Landscape. J Diabetes. 2025 Jun; 17(6):e70108. Hou W, Tuttle KR, Shen W, Reikes A, Watanabe JH. PMID: 40464139; PMCID: PMC12134773.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a real-world database. Expert Rev Endocrinol Metab. 2025 Mar; 20(2):163-168. Kwon J, Thiara D, Watanabe JH. PMID: 39921267.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. ASHP and ASHP Foundation Pharmacy Forecast 2025: Strategic Planning Guidance for Pharmacy Departments in Hospitals and Health Systems. Am J Health Syst Pharm. 2025 01 06; 82(2):17-47. DiPiro JT, Hoffman JM, Tichy E, Shea S, Sanborn M, Hung A, Fox ER, Watanabe JH, Torrise V, Abourjaily P, Cunningham FE, Schweitzer P, Nelson SD, Stump LS, Castro H, Nesbit TW, Scott CM. PMID: 39657700.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Examining the impact of Anticholinergic Burden on Hospitalized Older People Receiving Concomitant Cholinesterase inhibitors. Sr Care Pharm. 2024 Dec 01; 39(12):449-457. Guan J, Noviasky J, Watanabe JH. PMID: 39627800.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Regulatory Processes for Rare Disease Drugs in the United States and European Union: Flexibilities and Collaborative Opportunities. 2024. View Publication.
    10. Preparing the Future Workforce in Drug Research and Development: Proceedings of a Workshop. 2024. View Publication.
    11. Enhancing drug evaluation in diverse populations and older adults: National Academies of Sciences, Engineering, and Medicine considerations. J Am Geriatr Soc. 2024 Sep; 72(9):2912-2920. Watanabe JH. PMID: 39017394.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Examining the Impact of the World Health Organization 2022 Guidelines on Evaluation of Biosimilars for Non-Local Comparators in Biosimilar Studies on Middle East and North Africa Member States. Pharmacy (Basel). 2024 Jun 16; 12(3). Strand MW, Watanabe JH. PMID: 38921970; PMCID: PMC11207457.
      View in: PubMed   Mentions: 1  
    13. Aspirin Use in Older People Highlights the Need for Improved Inclusion of Older People in Clinical Trials. Sr Care Pharm. 2024 Jun 01; 39(6):209-211. Watanabe JH, Zajac D. PMID: 38803025.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Advancing Clinical Research with Pregnant and Lactating Populations: Overcoming Real and Perceived Liability Risks. 2024. View Publication.
    15. Association of Pre-Pandemic Telehealth With Emergency Department and Telehealth Usage During the Pandemic. Sr Care Pharm. 2024 Mar 01; 39(3):105-112. Strand M, Watanabe JH. PMID: 38379135.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    16. Considerations on the Weight Loss-Associated Glucagon-like Peptide-1 Receptor Agonists for Older People. Sr Care Pharm. 2023 Dec 01; 38(12):493-496. Watanabe JH. PMID: 38041227.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003). 2024 Jan-Feb; 64(1):133-138. Watanabe JH, Kwon J, Nan B, Reikes A. PMID: 37821008.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    18. Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare-Medicaid Populations in a Historic Database. Pharmacy (Basel). 2023 Sep 07; 11(5). Watanabe JH, Hoang T. PMID: 37736912; PMCID: PMC10514781.
      View in: PubMed   Mentions:
    19. Improving Care for Opioid Use Disorder in Nursing Facilities. Sr Care Pharm. 2023 08 01; 38(8):309-310. Watanabe JH. PMID: 37496169.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Effectiveness of letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A global systematic review. J Am Pharm Assoc (2003). 2023 Jul-Aug; 63(4):1138-1149. Sepassi A, Saunders IM, Bounthavong M, Taplitz RA, Logan C, Watanabe JH. PMID: 37207713.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    21. Research with Pregnant and Lactating Persons: Mitigating Risk and Liability: Proceedings of a Workshop—in Brief. 2023. View Publication.
    22. Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States. Pharmacoecon Open. 2023 May; 7(3):393-404. Sepassi A, Saunders IM, Bounthavong M, Taplitz RA, Logan C, Watanabe JH. PMID: 36840894; PMCID: PMC10169956.
      View in: PubMed   Mentions: 5  
    23. The Critical Role of Pharmacists in Treating Older People in the Opioid Crisis. Sr Care Pharm. 2023 Feb 01; 38(2):47-49. Watanabe JH. PMID: 36751937.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    24. Minding the gap and the value of metrics: Count of working pharmacists in the United States. J Am Pharm Assoc (2003). 2023 May-Jun; 63(3):899-903. Hirsch JD, Nguyen MH, Abugazia J, Watanabe JH. PMID: 36631343.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Responding to "Senior Care Pharmacists Must Be the Disruptive Force that Reduces Adverse Drug Events in Older People". Sr Care Pharm. 2022 09 01; 37(9):380-381. Khartabil N, Watanabe JH. PMID: 36039001.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US. JAMA Health Forum. 2022 08 05; 3(8):e222839. Qato DM, Watanabe JH, Clark KJ. PMID: 36218988.
      View in: PubMed   Mentions: 13     Fields:    
    27. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. 2022. View Publication.
    28. Senior Care Pharmacists Must Be the Disruptive Force that Reduces Adverse Drug Events in Older People. Sr Care Pharm. 2022 07 01; 37(7):247-249. Watanabe JH. PMID: 35752921.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Effects of financial toxicity on prescription drug use and mental well-being in cancer patients. Explor Res Clin Soc Pharm. 2022 Jun; 6:100136. Chan K, Sepassi A, Saunders IM, Goodman A, Watanabe JH. PMID: 35909716; PMCID: PMC9335927.
      View in: PubMed   Mentions: 5  
    30. Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large Statewide Health System During the Pandemic in 2020. J Pharm Technol. 2022 Apr; 38(2):75-87. Watanabe JH, Kwon J, Nan B, Abeles SR, Mehta SR. PMID: 35571345; PMCID: PMC9096847.
      View in: PubMed   Mentions: 1  
    31. Risk of Negative Health Outcomes and High Costs for People With Diabetes and Unmet Psychological Needs in the United States. Diabetes Spectr. 2022; 35(2):207-215. Sepassi A, Bounthavong M, Singh RF, Heyman M, Beizai K, Watanabe JH. PMID: 35668883; PMCID: PMC9160558.
      View in: PubMed   Mentions:
    32. Envisioning a Transformed Clinical Trials Enterprise for 2030: Proceedings of a Workshop. 2021. View Publication.
    33. Transferring Key Success Factors from Ambulatory Care into the Community Pharmacy in the United States. Pharmacy (Basel). 2021 Jun 23; 9(3). Luli AJ, Awdishu L, Hirsch JD, Watanabe JH, Bounthavong M, Morello CM. PMID: 34201476; PMCID: PMC8293369.
      View in: PubMed   Mentions: 4  
    34. Association of Age and Hospitalization Amongst Those with Underlying High-risk Conditions at COVID-19 Diagnosis in a Large, State-wide Health System. J Gen Intern Med. 2021 09; 36(9):2906-2908. Watanabe JH, Kwon J, Mehta SR. PMID: 34137004; PMCID: PMC8208375.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. When Can We Trust Real-World Data To Evaluate New Medical Treatments? Clin Pharmacol Ther. 2022 01; 111(1):24-29. Simon GE, Bindman AB, Dreyer NA, Platt R, Watanabe JH, Horberg M, Hernandez A, Califf RM. PMID: 33932030; PMCID: PMC9292968.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    36. When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments? Clin Pharmacol Ther. 2022 01; 111(1):30-34. Simon GE, Platt R, Watanabe JH, Bindman AB, John London A, Horberg M, Hernandez A, Califf RM. PMID: 33895994; PMCID: PMC8251042.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    37. When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? Clin Pharmacol Ther. 2022 01; 111(1):108-115. Franklin JM, Platt R, Dreyer NA, London AJ, Simon GE, Watanabe JH, Horberg M, Hernandez A, Califf RM. PMID: 33826756; PMCID: PMC9291272.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    38. Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic. JAMA Netw Open. 2021 05 03; 4(5):e2110775. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. PMID: 34019090; PMCID: PMC8140369.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsPHPublic Health
    39. When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials? Clin Pharmacol Ther. 2022 01; 111(1):116-121. Watanabe JH, Simon GE, Horberg M, Platt R, Hernandez A, Califf RM. PMID: 33829639; PMCID: PMC9290851.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. DISCARDED MEDICATIONS IN VIALS ARE A SYMPTOM OF OUR HEALTH CARE SYSTEM: A CALL TO ACTION. J Manag Care Spec Pharm. 2021 May; 27(5):689-690. Watanabe JH, Lieu T, Shortliffe EH. PMID: 33908281; PMCID: PMC10390907.
      View in: PubMed   Mentions:    Fields:    Translation:PHPublic Health
    41. Medications in Single-Dose Vials: Implications of Discarded Drugs. 2021. View Publication.
    42. Associations of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with Colorectal Cancer Risk in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2021 05; 30(5):1029-1032. Brasky TM, Flores KF, Larson JC, Newton AM, Shadyab AH, Watanabe JH, Lane DS, Thomson CA, LaCroix AZ. PMID: 33627382; PMCID: PMC8102324.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population. J Manag Care Spec Pharm. 2021 Apr; 27(4):478-487. Kazerooni R, Watanabe JH. PMID: 33511895; PMCID: PMC10394205.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. Drug Research and Development for Adults Across the Older Age Span: Proceedings of a Workshop. 2021. View Publication.
    45. Pharmacist-directed care to optimize medication use: a healthcare imperative in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020 Oct; 20(5):419-421. Watanabe JH. PMID: 32902351.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. Association of combination opioid, benzodiazepine, and muscle relaxant usage with emergency department visits in a nationwide cohort in the United States. Int J Clin Pharm. 2021 Apr; 43(2):358-364. Watanabe JH, Yang J. PMID: 32266557.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    47. Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. J Am Pharm Assoc (2003). 2020 Mar - Apr; 60(2):297-303. Luli AJ, Bounthavong M, Watanabe JH. PMID: 31889651.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    48. Hospitalization and Combined Use of Opioids, Benzodiazepines, and Muscle Relaxants in the United States. Hosp Pharm. 2020 Oct; 55(5):286-291. Watanabe JH, Yang J. PMID: 32999498; PMCID: PMC7502868.
      View in: PubMed   Mentions: 6  
    49. Advancing Pharmacist Collaborative Care within Academic Health Systems. Pharmacy (Basel). 2019 Oct 11; 7(4). Awdishu L, Singh RF, Saunders I, Yam FK, Hirsch JD, Lorentz S, Atayee RS, Ma JD, Tsunoda SM, Namba J, Mnatzaganian CL, Painter NA, Watanabe JH, Lee KC, Daniels CD, Morello CM. PMID: 31614555; PMCID: PMC6958419.
      View in: PubMed   Mentions: 11  
    50. Examining the Pharmacist Labor Supply in the United States: Increasing Medication Use, Aging Society, and Evolution of Pharmacy Practice. Pharmacy (Basel). 2019 Sep 19; 7(3). Watanabe JH. PMID: 31546891; PMCID: PMC6789639.
      View in: PubMed   Mentions: 4  
    51. Policy impact: When policy fails. Nurs Forum. 2020 Jan; 55(1):37-44. Davidson JE, Marshall MF, Watanabe JH. PMID: 31432541.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Emergency Department Visits for Psychotropic-Related Adverse Drug Events in Older Adults With Alzheimer Disease, 2013-2014. Ann Pharmacother. 2019 12; 53(12):1173-1183. Sepassi A, Watanabe JH. PMID: 31342766.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. Anxiety and Depression Symptoms and Every-Night Sleep Medication Use in Older Adults. Sr Care Pharm. 2019 Jul 01; 34(7):449-455. Watanabe JH, Chau DL. PMID: 31383056.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Medications for Opioid Use Disorder Save Lives. 2019. View Publication.
    55. Examining the Impact of Real-World Evidence on Medical Product Development: Proceedings of a Workshop Series. 2019. View Publication.
    56. Medication-Assisted Treatment for Opioid Use Disorder: Proceedings of a Workshop—in Brief. 2018. View Publication.
    57. Anticoagulant Use in High Stroke-Risk Patients With Nonvalvular Atrial Fibrillation. Consult Pharm. 2018 Sep 01; 33(9):521-530. Nguyen HK, Humber D, Checkoway H, Blanchard D, Watanabe JH. PMID: 30185292.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015. J Am Geriatr Soc. 2018 08; 66(8):1621-1624. Watanabe JH, Chau DL, Hirsch JD. PMID: 29972589.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother. 2018 09; 52(9):829-837. Watanabe JH, McInnis T, Hirsch JD. PMID: 29577766.
      View in: PubMed   Mentions: 127     Fields:    Translation:Humans
    60. Making Medicines Affordable: A National Imperative. 2017. View Publication.
    61. Medication Regimen Complexity in Long-Term Care Facilities and Adverse Drug Events-Related Hospitalizations. Consult Pharm. 2017 May 01; 32(5):281-284. Tam SHY, Hirsch JD, Watanabe JH. PMID: 28483008.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    62. Medication Use, Falls, and Fall-Related Worry in Older Adults in the United States. Consult Pharm. 2016 Jul; 31(7):385-93. Watanabe JH. PMID: 27412315.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    63. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Res Social Adm Pharm. 2017 May - Jun; 13(3):530-538. Bounthavong M, Li M, Watanabe JH. PMID: 27263802.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    64. Value of Information in Asia: Concepts, Current Use, and Future Directions. Value Health Reg Issues. 2016 May; 9:99-104. Dilokthornsakul P, McQueen RB, Chaiyakunapruk N, Spackman E, Watanabe JH, Campbell JD. PMID: 27881269.
      View in: PubMed   Mentions:    Fields:    
    65. Definition and Classification of Generic Drugs Across the World. Appl Health Econ Health Policy. 2015 Aug; 13 Suppl 1:S5-11. Alfonso-Cristancho R, Andia T, Barbosa T, Watanabe JH. PMID: 26091708; PMCID: PMC4519628.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    66. Approach to addressing missing data for electronic medical records and pharmacy claims data research. Pharmacotherapy. 2015 Apr; 35(4):380-7. Bounthavong M, Watanabe JH, Sullivan KM. PMID: 25884526.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    67. Association of increased emergency rooms costs for patients without access to necessary medications. Res Social Adm Pharm. 2015 Jul-Aug; 11(4):499-506. Watanabe JH, Ney JP. PMID: 25487421.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014 Jan; 20(1):43-50. Watanabe JH, Kazerooni R, Bounthavong M. PMID: 24372459; PMCID: PMC10437734.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    69. Association of polypharmacy and statin new-user adherence in a Veterans Health Administration population: a retrospective cohort study. Ann Pharmacother. 2013 Oct; 47(10):1253-9. Watanabe JH, Bounthavong M, Chen T, Ney JP. PMID: 24259688.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    70. Association of copayment and statin adherence stratified by socioeconomic status. Ann Pharmacother. 2013 Nov; 47(11):1463-70. Kazerooni R, Bounthavong M, Watanabe JH. PMID: 24259605.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. Association between statin adherence and cholesterol level reduction from baseline in a veteran population. Pharmacotherapy. 2013 Oct; 33(10):1044-52. Kazerooni R, Watanabe JH, Bounthavong M. PMID: 23744794.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    72. Cost-benefit analysis: intraoperative neurophysiological monitoring in spinal surgeries. J Clin Neurophysiol. 2013 Jun; 30(3):280-6. Ney JP, van der Goes DN, Watanabe JH. PMID: 23733093.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    73. Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med. 2013 May; 14(5):706-19. Ney JP, Devine EB, Watanabe JH, Sullivan SD. PMID: 23691937.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    74. Revisiting the medication possession ratio threshold for adherence in lipid management. Curr Med Res Opin. 2013 Mar; 29(3):175-80. Watanabe JH, Bounthavong M, Chen T. PMID: 23320610.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    75. Cost-effectiveness of intraoperative neurophysiological monitoring for spinal surgeries: beginning steps. Clin Neurophysiol. 2012 Sep; 123(9):1705-7. Ney JP, van der Goes DN, Watanabe JH. PMID: 22386320.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    76. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. PMID: 21275440.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    77. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010 Oct; 76(4):835-40. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. PMID: 20430422.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    78. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol. 2009 Nov 20; 9:18. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. PMID: 19930578; PMCID: PMC2788579.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    Jonathan's Networks
    Concepts (222)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (29)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-18-gb39b692b on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.